Resources

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.

Health professionals can print this fact sheet and give it to patients who are starting treatment under the Life Saving Drugs Program.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for HPP.

Treating physicians use this application form to apply for a patient to access LSDP medication for HPP for the first time, or after a break.

These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.

This document outlines 51 recommendations from the Life Saving Drugs (LSDP) expert panel review.

A Budget 2022–23 fact sheet.

This fact sheet outlines accessing medicines through electronic prescriptions.

Electronic prescribing has been fast-tracked as part of the National Health Plan for coronavirus (COVID-19). This guide for pharmacists outlines the temporary arrangements available now that will help patients receive medicines via telehealth services.

Electronic prescribing has been fast-tracked as part of the National Health Plan for coronavirus (COVID-19). This guide for prescribers outlines the temporary arrangements available now that will help patients receive medicines via telehealth services.

A Budget 2022–23 fact sheet.

A Budget 2022–23 fact sheet.

This fact sheet outlines how and when oral treatments for COVID-19 will be administered in residential aged care facilities.

This fact sheet explains changes to the way we provide access to eculizumab (Soliris®) for patients with paroxysmal nocturnal haemoglobinuria from 1 March 2022.

This fact sheet for prescribers explains changes to the way we provide access to eculizumab (Soliris®) for patients with paroxysmal nocturnal haemoglobinuria from 1 March 2022. It outlines what prescribers need to do to transition their patients to the new arrangements.

This fact sheet outlines the key considerations of introducing Paxlovid® (nirmatrelvir + ritonavir) into residential aged care clinical practices.

This policy describes how personal information and related data contained in electronic prescriptions is collected, used and disclosed.

This policy outlines the privacy responsibilities of non-government organisations involved in the electronic prescribing process.

The Electronic Prescriptions Security and Access Policy describes how health care provider organisations must manage the security and integrity of their software, to make sure they dispense electronic prescriptions securely.